Healthcare Roundup – Eli Lilly targets buying spree, MCOA inks deal for CBD beverage products

医疗保健精选——礼来2020年疯狂收购,MCOA达成CBD饮料交易
Published on: January 17, 2020
Author: Amy Liu

Eli Lilly targets buying spree in 2020

  • Looking to build up its pipeline of future products, Eli Lilly (NYSE:LLY) aims to announce a $1B-5B deal for each quarter of 2020.
  • The acquisitions will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters.
  • The spree has already started. Last week, Eli Lilly announced a deal to buy dermatology products maker Dermira for $1.1B.

MCOA inks deal for CBD beverage products

  • Marijuana Company of America’s (OTCQB:MCOA) wholly owned subsidiary, hempSMART Inc., has signed a definitive sales agreement to purchase ultra-clean label CBD beverage products from MCTC Holdings (OTCPK:MCTC).
  • During the initial stage, MCOA will offer a line of powdered drink mixes containing hemp extracts with over 35 milligrams of CBD derived from all-natural extraction processes.
  • Future offerings will include other powdered and pre-mixed beverages.

Allergan launches new eye cream

  • Allergan (NYSE:AGN) has launched SkinMedica Instant Bright Eye Cream, an eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes.
  • SkinMedica is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.
  • Instant Bright products will be available for purchase online beginning April 2020.

MCig receives purchase order for CBD-based products

  • MCig (OTCPK:MCIG) subsidiary, BareRoots Rx Inc., the consumer products division, has entered into an agreement to distribute 10,000 monthly boxes of the CBD-based products to select tribal communities.
  • The company anticipates revenue of ~$1.1M in its first year of operation under the agreement and has also entered into a white labeling agreement with the cannabis company to supply ~$200,000 of CBD derivative products.

Tetra Bio to launch Terpacan products mid-year

  • Tetra Bio-Pharma (OTCQB:TBPMF) announces that Health Canada has issued two Drug Identification Numbers for its first OTC topical Terpacan products, one for hemorrhoids and the other for back & muscle pain.
  • Commercial launch in Canada will commence mid-year followed by launches in the U.S. and Europe (after regulatory approvals).

Healthcare Services Life Science Pharmaceutical